$RVTY

T. Rowe Price Associates (RVTY) discloses 5.0% beneficial stake in Revvity

T. Rowe Price Associates, Inc. filed Amendment No. 4 to a Schedule 13G/A for Revvity Inc. It reported beneficial ownership of 5,526,874 shares, or 5.0% of the class, as of June 30, 2026. The filing lists sole voting power of 5,508,363 shares and sole dispositive power of 5,526,874 shares.

Original reporting
Published Aug 14, 2026, 2:39 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 15, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$RVTY
Neutral
medium confidence
Mentioned
$RVTY
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$RVTYNeutralLow
01

Why it matters

For RVTY, the new detail is the size of T. Rowe Price’s beneficial stake (5.0%) and the fact it has sole voting and dispositive power over the reported shares.

02

Market read

Traders may monitor for follow-on 13D/13G changes or governance signals, but this specific filing alone does not indicate an active control effort.

03

What to watch

The filing states it should not be construed as an admission of beneficial ownership, and it is passive (Schedule 13G), which reduces the likelihood of immediate governance action.

Relevance 4/10Novelty 5/10Timing: filing disclosed Aug 14, 2026

Background

Schedule 13G/A amendments disclose beneficial ownership stakes, typically when holdings exceed a threshold and the filer claims passive intent.

Company-level read

Ticker impact

$RVTYNeutralMedium confidence
Context

T. Rowe Price Associates filed a Schedule 13G/A showing 5.0% beneficial ownership of Revvity as of June 30, 2026.

Expected impact

Likely limited near-term price impact; any effect would be through sentiment/positioning rather than fundamentals.

Evidence & confidence

The article provides the updated beneficial ownership percentage and voting/dispositive power, but no accompanying deal, governance change, or fundamental guidance.

Market effects

Minimal, since the disclosure is company-specific and does not indicate sector-wide regulatory or demand changes.

None indicated.

None indicated.

Counterpoint

A Schedule 13G/A can reflect routine passive investing or hedging, so the market may overreact to the 5% headline without any active campaign.

Key entities

  • RVTY

    Revvity Inc., the issuer whose common stock beneficial ownership was disclosed.

  • T. Rowe Price Associates, Inc.

    Filed Amendment No. 4 to Schedule 13G/A reporting beneficial ownership as of June 30, 2026.

Related articles

$RVTYHighAI 9/10

Revvity (RVTY) Q2 2026 Earnings Call Transcript

Revvity (RVTY) reported Q2 2026 pro forma revenue of $711 million, up 3% organically, and pro forma adjusted EPS of $1.41. Diagnostics revenue rose 11% organically, while Signals software declined 20% organically. Free cash flow was $184 million. Full-year organic growth guidance was raised to 4% to 5% and adjusted EPS to $5.30 to $5.40.

$RVTYMedAI 8/10

Revvity Q2 Earnings Call Highlights

Revvity (RVTY) reported Q2 results on an earnings call, with Diagnostics revenue of $352M up 12% reported and 11% organic. Life Sciences revenue was $359M, down 2% reported and 3% organic, driven by a ~20% Signals software decline. For 2026, it raised pro forma organic growth to 4%-5% and guided revenue $2.83B-$2.86B, adjusted EPS $5.30-$5.40. It expects Q3 revenue $685M-$700M and organic growth 4%-6%.

$RVTYMed

Revvity, Inc. Q2 2026 Earnings Call Summary

Revvity, Inc. reported Q2 2026 results, citing improving pharma and biotech spending and higher orders tied to AI-driven drug discovery. Management said Opera Phenix OptIQ demand outpaces capacity, raised full-year organic growth guidance to 4% to 5%, and expects Signals software double-digit growth in H2. It signed an agreement to divest China immunodiagnostics and targets gross leverage below 3x by year-end.

$RVTYMedAI 8/10

Why Revvity (RVTY) Stock Is Up Today

Revvity (NYSE: RVTY) shares rose about 3% after the company reported Q2 2026 adjusted EPS of $1.41 versus $1.21 expected, and revenue of $729.68 million versus $703.39 million. Revvity lifted full-year guidance to 4% to 5% organic growth and EPS of $5.30 to $5.40. Stifel raised its target to $110 and Bernstein to $120.

$RVTYMedAI 9/10

RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up

Revvity (RVTY) reported Q2 2026 adjusted EPS of $1.41, up 19.5% and above the $1.23 Zacks estimate. Revenue rose 1.3% to $729.7 million, beating $704.5 million. Pro forma revenues were $711.1 million. Diagnostics grew; Life Sciences declined. Revvity raised 2026 pro forma revenue to $2.83-$2.86B and EPS to $5.30-$5.40 and agreed to divest China Immunodiagnostics.